Edition:
United Kingdom

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

2.19USD
4:45pm GMT
Change (% chg)

$-0.16 (-6.81%)
Prev Close
$2.35
Open
$2.35
Day's High
$2.48
Day's Low
$2.08
Volume
206,357
Avg. Vol
85,818
52-wk High
$2.82
52-wk Low
$0.90

Select another date:

Wed, Nov 8 2017

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

BRIEF-Second sight receives German approval to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients

* Second Sight receives approval from Bundesinstitut Für Arzneimittel Und Medizinprodukte in Germany to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives conditional FDA approval to begin first Orion human clinical study

* Second sight receives conditional FDA approval to begin first Orion human clinical study

BRIEF-Second Sight Medical Products Q2 sales $2.2 mln

* Says total revenue was $2.2 million for q2 of 2017, compared with $1.0 million in q2 of 2016 Source text for Eikon: Further company coverage:

BRIEF-Second Sight Medical Products submits application for IDE with FDA

* Second Sight Medical Products - submitted application for IDE with FDA for approval to conduct early feasibility study of orioncortical visual prosthesis system

BRIEF-Second Sight Medical Products says Thomas Miller notified company he was submitting his resignation as CFO

* Second Sight Medical Products Inc - On June 20, 2017, Thomas B. Miller, CFO notified company he was submitting his resignation as Chief Financial Officer

Select another date: